157 related articles for article (PubMed ID: 17767547)
1. The immunoinformatics of cancer immunotherapy.
Deluca DS; Blasczyk R
Tissue Antigens; 2007 Oct; 70(4):265-71. PubMed ID: 17767547
[TBL] [Abstract][Full Text] [Related]
2. Integrated modeling of the major events in the MHC class I antigen processing pathway.
Dönnes P; Kohlbacher O
Protein Sci; 2005 Aug; 14(8):2132-40. PubMed ID: 15987883
[TBL] [Abstract][Full Text] [Related]
3. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
[TBL] [Abstract][Full Text] [Related]
4. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.
Leone P; Shin EC; Perosa F; Vacca A; Dammacco F; Racanelli V
J Natl Cancer Inst; 2013 Aug; 105(16):1172-87. PubMed ID: 23852952
[TBL] [Abstract][Full Text] [Related]
5. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding.
Tenzer S; Peters B; Bulik S; Schoor O; Lemmel C; Schatz MM; Kloetzel PM; Rammensee HG; Schild H; Holzhütter HG
Cell Mol Life Sci; 2005 May; 62(9):1025-37. PubMed ID: 15868101
[TBL] [Abstract][Full Text] [Related]
6. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes.
Hung CF; Cheng WF; He L; Ling M; Juang J; Lin CT; Wu TC
Cancer Res; 2003 May; 63(10):2393-8. PubMed ID: 12750257
[TBL] [Abstract][Full Text] [Related]
7. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.
Vigneron N; Abi Habib J; Van den Eynde BJ
Trends Cancer; 2017 Oct; 3(10):726-741. PubMed ID: 28958390
[TBL] [Abstract][Full Text] [Related]
8. Insights on the HLA-Binding Peptidome in Cancer.
Lake DF
Enzymes; 2017; 42():81-103. PubMed ID: 29054272
[TBL] [Abstract][Full Text] [Related]
9. How selective is the transporter associated with antigen processing?
Androlewicz MJ; Cresswell P
Immunity; 1996 Jul; 5(1):1-5. PubMed ID: 8758889
[No Abstract] [Full Text] [Related]
10. Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.
Storkus WJ; Herrem C; Kawabe M; Cohen PA; Bukowski RM; Finke JH; Wesa AK
Crit Rev Immunol; 2007; 27(5):485-93. PubMed ID: 18197809
[TBL] [Abstract][Full Text] [Related]
11. Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
Humphreys RE; Hillman GG; von Hofe E; Xu M
Cell Mol Immunol; 2004 Jun; 1(3):180-5. PubMed ID: 16219165
[TBL] [Abstract][Full Text] [Related]
12. High-Throughput Prediction of MHC Class I and II Neoantigens with MHCnuggets.
Shao XM; Bhattacharya R; Huang J; Sivakumar IKA; Tokheim C; Zheng L; Hirsch D; Kaminow B; Omdahl A; Bonsack M; Riemer AB; Velculescu VE; Anagnostou V; Pagel KA; Karchin R
Cancer Immunol Res; 2020 Mar; 8(3):396-408. PubMed ID: 31871119
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy: novel strategies and clinical experiences.
Schmitz M; Bornhäuser M; Ockert D; Rieber EP
Trends Immunol; 2002 Sep; 23(9):428-9. PubMed ID: 12200057
[No Abstract] [Full Text] [Related]
14. MHC class I antigen presentation: learning from viral evasion strategies.
Hansen TH; Bouvier M
Nat Rev Immunol; 2009 Jul; 9(7):503-13. PubMed ID: 19498380
[TBL] [Abstract][Full Text] [Related]
15. Chemical biology of antigen presentation by MHC molecules.
van Kasteren SI; Overkleeft H; Ovaa H; Neefjes J
Curr Opin Immunol; 2014 Feb; 26():21-31. PubMed ID: 24556397
[TBL] [Abstract][Full Text] [Related]
16. Metadherin peptides containing CD4(+) and CD8(+) T cell epitopes as a therapeutic vaccine candidate against cancer.
Dhiman G; Lohia N; Jain S; Baranwal M
Microbiol Immunol; 2016 Sep; 60(9):646-52. PubMed ID: 27554419
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
18. Tumour surveillance: missing peptides and MHC molecules.
Khanna R
Immunol Cell Biol; 1998 Feb; 76(1):20-6. PubMed ID: 9553772
[TBL] [Abstract][Full Text] [Related]
19. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.
Thiele F; Tao S; Zhang Y; Muschaweckh A; Zollmann T; Protzer U; Abele R; Drexler I
J Virol; 2015 Mar; 89(5):2698-709. PubMed ID: 25520512
[TBL] [Abstract][Full Text] [Related]
20. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
